BlogHotel.orgAccueil | Créer un blog | Imprimer la page Imprimer | Blog hasard Au hasard | Chercher des blogs Rechercher | Entrer dans le chat du blog Chat | | Jeux Jeux | Adminitration et édition du Blog Manager

freemexy Accueil | Profil | Archives | Amis
freemexy

MSD changing Chinese lives8/11/2019
Thirty years ago, pharmaceutical company MSD made a decision that may have changed the lives of millions of people in China: it agreed to conduct technology transfer of hepatitis B vaccine to China — possibly the country that needed it most at that time.The second China International Import Expo will be held at the National Exhibition and Convention Center in Shanghai from November 5 to 10, 2019.For further information about China International Import Expo, please visit: https://www.shine.cn/China-International-Import-Expo/ or
https://www.shine.cn/ciie2019/v1.To get more China International Import Expo, you can visit shine news official website.

To commemorate this milestone decision, MSD China held a cerebration at the ongoing China International Import Expo, and promised to continue its journey of facilitating China’s public health.“Public health is beyond borders, and this technology transfer 30 years ago may be one of the best decisions for the 20th century,” said Joseph Romanelli, senior vice president of MSD and president of MSD in China.

In 1980s, hepatitis B was a serious disease threatening Chinese people’s health. At the same time, MSD had developed the then world's most advanced recombinant DNA hepatitis B vaccine and launched it in the United States in 1986.In order to solve HBV infection, MSD decided to transfer HBV vaccine technology to China in 1989 and to help instruct and train Chinese scientists and engineers.

“At the beginning, we hoped to sell HBV vaccine to China. But even if its price was lowered to the minimum level, Chinese families might still not be able to afford it,” Roy Vagelos, former MSD CEO and chairman, wrote in his memoirs. "The situation was so urgent and I wanted to protect children from this deadly disease."

In the final contract signed with the Chinese government, MSD promised neither to charge any patent fee or profit, nor sell HBV vaccine produced by MSD on the Chinese mainland. Vagelos said: “MSD was trying to use this technology to solve a huge medical problem and help those who faced the risks of the diseases but could not afford it.”Later, MSD helped establish HBV vaccine production sites in Beijing and Shenzhen to ensure the quality of HBV vaccine produced in China was no different to that in the US.

In 1993, China produced the first batch of recombinant HBV vaccines and began to use them. In 2002, HBV vaccine was included in the China National Immunization Program, thus more newborns have been protected from mother-to-child HBV infection.In May 2012, China received a certificate from the World Health Organization, saying it had achieved the goal of reducing the chronic HBV infection rate among children under five to below 2 percent and had set a good example for other developing countries.

In 2014, the WHO praised the Chinese government in recognition of China's outstanding achievements in the prevention and control of HBV related disease mainly due to the high vaccination rate among children and a 95 percent plus vaccination rate among newborns.

“It was an unforgettable journey and resonated the principle of MSD that we are here first to help people who need help,” said Romanelli.MSD has been committed to developing innovative medicines and vaccines to build a “health Great Wall” for the general public.

At the CIIE, MSD displays its innovative products and R&D pipelines in oncology, vaccine, diabetes and anti-infection at its booth under the theme of “Inventing for Life.” “China’s deepening health-care reform has provided new opportunities for MSD,” said Romanelli, who said he had a firm belief that the process would gain further momentum. “We can feel it here at the CIIE that China has committed even further in its opening-up process.”

In 2018, MSD had nine innovative drugs and vaccines approved in China — ranging from preventative vaccines to cancer immunotherapy drugs that save lives.

0 Commentaires | poster un commentaire | Lien Permanent

No Evidence Furosemide Contributes To Breakdowns4/11/2019
The Scientific Advisory Group of the Association of Racing Commissioners International (ARCI) has reported that there is no current science linking furosemide treatments to muscular skeletal issues that may be a contributing cause of equine breakdowns in racing.wisepoqder Furosemide

The group reported to a meeting of the RCI's Drug Testing Standards and Practices Committee that they discussed the issue at their meeting on April 2, 2019 and were not aware of any published studies or papers providing any evidence of such a link.

The Scientific Advisory Group members participating in the meeting were: Dr. Scot Stanley, Dr. Heather Kynch, Dr. George Maylin, Dr. Ken McKeever, Dr. Cynthia Cole, Dr. Mary Robinson, Dr. Rick Sams, and Dr. Thomas Tobin.

“There remains an attempt on the part of some organizations and individuals to leave the impression that the current equine welfare policy of permitting the voluntary race day use of furosemide under controlled and transparent circumstances is somehow tied to the tragic equine deaths that have occurred at Santa Anita and elsewhere,” said ARCI President Ed Martin in a statement.The ARCI is never averse to examining an existing policy and we were concerned that such statements might be based upon solid scientific information we have yet been able to analyze. Apparently, they are not. Our science advisors were asked to review this matter and make us aware of any new information that might be relevant to the equine tragedies that have occurred,” he said.

In 2011, after two RCI officers called for the phase out of race day furosemide treatments, an industry debate on the issue was reignited. The Drug Testing Standards and Practices Committee conducted a review of the existing policy and held a public hearing during the Saratoga meet.

Input was received from a variety of experts, including Dr. N. Edward Robinson from the Center for Integrative Toxicology at the Veterinary Medical Center at Michigan State University. Dr. Robinson is a recognized expert in the study of animal lung dysfunction, particularly equine airway disease. He directs the Equine Pulmonary Research Laboratory at MSU which is dedicated to studying the pathogenesis and treatment of diseases of the air passages (airways) of the horse.

After completion of that review, the committee decided that there was insufficient science to justify change to the current policy.

The rationale for current furosemide policy was strengthened by a 2014 Consensus statement from the independent American College of Veterinary Internal Medicine (ACVIM) published in the Journal of Veterinary Internal Medicine entitled Exercise Induced Pulmonary Hemorrhage in Horses.

0 Commentaires | poster un commentaire | Lien Permanent

Page 211 of 834
Précédent | Suivant